SCHEMBL13615467

SCHEMBL13615467

CC=C1C(=O)NC(=O)NC1=O

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.45
KDM4E B2RXH2 3/20 0.45
OGT O15294 1/20 0.45
USP2 O75604 1/20 0.45
RECQL P46063 1/20 0.45
BLM P54132 1/20 0.45
METAP1 P53582 8/20 0.41
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
POLB P06746 1/20 0.38
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21675668 0.81 SMN1; SMN2 (0.31) METAP1
SCHEMBL6745671 0.74
SCHEMBL12645490 0.74
SCHEMBL5487108 0.73 MAPT (0.47) MAPTKDM4EOGTUSP2RECQL
SCHEMBL20362831 0.72 MAPT (0.41) MAPTKDM4EOGTUSP2RECQL
SCHEMBL123424 0.69
SCHEMBL12014049 0.69 METAP1 (0.45) MAPTKDM4EOGTUSP2RECQL
SCHEMBL4428107 0.65 METAP1 (0.80) MAPTKDM4EMETAP1KMT2APOLB
SCHEMBL19563003 0.65 KDM4E (0.33) MAPTKDM4EOGTUSP2RECQL
SCHEMBL12013780 0.65 METAP1 (0.46) MAPTKDM4EOGTUSP2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870624-B2 Histone deacetylase inhibitors KARUS THERAPEUTICS LIMITED (GB) 2020-12-22 US disclosed
US-20180170876-A1 NOVEL HISTONE DEACETYLASE INHIBITORS KARUS THERAPEUTICS LIMITED (GB) 2018-06-21 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-9567305-B2 Quinoxaline compounds and derivatives SOUTHERN METHODIST UNIVERSITY (US) 2017-02-14 US disclosed
US-20160235752-A1 COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT UNIVERSITY OF NEW ORLEANS (US) 2016-08-18 US disclosed
US-20160168165-A1 MYC MODULATORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-06-16 US disclosed
WO-2016094688-A1 FUSED 1,3-AZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2016-06-16 WO disclosed
US-9190617-B2 Photoelectric conversion element and solar cell KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2015-11-17 US disclosed
US-9190617-B2 Photoelectric conversion element and solar cell KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2015-11-17 US disclosed
US-20130125987-A1 PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR BATTERY CONTAINING THE SAME KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2013-05-23 US disclosed
US-20130125987-A1 PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR BATTERY CONTAINING THE SAME KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2013-05-23 US disclosed
US-20130025682-A1 PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2013-01-31 US disclosed
US-20130025682-A1 PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2013-01-31 US disclosed
US-20120325319-A1 PHOTOELECTRIC CONVERSION ELEMENT, METHOD FOR PRODUCING PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2012-12-27 US disclosed
US-20120325319-A1 PHOTOELECTRIC CONVERSION ELEMENT, METHOD FOR PRODUCING PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2012-12-27 US disclosed
EP-2116585-A1 ULTRAVIOLET ABSORBER COMPOSITION Fujifilm Corporation (JP) 2009-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168165-A1 MYC MODULATORS AND USES THEREOF MYC, MYCBP, MYCBP2 MAPT 2226/4885KDM4E 2657/4885OGT 2553/4885
US-20160235752-A1 COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT LIPA, ELANE, CLPP MAPT 3305/4885KDM4E 3871/4885OGT 588/4885
US-20180170876-A1 NOVEL HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC5, HDAC11 MAPT 1987/4885KDM4E 146/4885OGT 2694/4885
US-10870624-B2 Histone deacetylase inhibitors HDAC1, HDAC5, HDAC2 MAPT 1674/4885KDM4E 133/4885OGT 2620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.